Scotiabank Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $41
Keros Therapeutics (KROS) Gets a Buy From Scotiabank
Keros Therapeutics Cut to Neutral From Overweight by Cantor Fitzgerald
Keros Therapeutics Analyst Ratings
Cantor Fitzgerald Downgrades Keros Therapeutics(KROS.US) to Hold Rating
Wedbush Downgrades Keros Therapeutics(KROS.US) to Hold Rating, Cuts Target Price to $15
Keros Therapeutics Downgraded to 'Hold' Amid Strategic Shifts and Program Removal
Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $15
Keros Therapeutics (KROS) Gets a Buy From Piper Sandler
Scotiabank Maintains Sector Outperform on Keros Therapeutics, Lowers Price Target to $41
Keros Therapeutics Is Maintained at Outperform by Oppenheimer
Keros Therapeutics Analyst Ratings
Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23
Oppenheimer Cuts Price Target on Keros Therapeutics to $23 From $63, Maintains Outperform Rating
Scotiabank Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $41
BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $32
Keros Therapeutics: Buy Rating Affirmed Despite Setbacks, Driven by Strong Pipeline and Strategic Partnerships
BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $33
Keros Therapeutics Is Maintained at Buy by Truist Securities
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $43